KB-0118

• Target :

  Interleukin|||STAT|||Epigenetic Reader Domain

• Related Pathways :

  Chromatin/Epigenetic|||JAK/STAT signaling|||Stem Cells|||Immunology/Inflammation

• Bioactivity :

  KB-0118 (BBC0115) is an inhibitor targeting the BET bromodomain. It selectively binds to BRD2 and BRD4, with dissociation constants (Kd) of 36.7 ?M for BRD2 BD1 and 47.4 ?M for BRD4 BD1, while not binding to BRD3. KB-0118 suppresses the secretion of pro-inflammatory cytokines such as TNF, IL-1?, and IL-23a, and selectively inhibits Th17 cell differentiation. The compound regulates Th17-driven inflammation through the epigenetic suppression of BRD4, as evidenced by the downregulation of STAT3 and BRD4 target genes. Additionally, KB-0118 exhibits immunomodulatory effects in inflammatory bowel disease (IBD) models.

• Smiles :

  O=C1C(O)=C(OC=2C=C(O)C=C(O)C12)C=3C=CC=4C=CNC4C3

• Molecular Formula :

  C17H11NO5

• Molecular Weight :

  309.27

• Shipping Conditions :

  Cool pack

• Storage Temperature :

  -20°C

• CAS Number :

  2648377-08-4